Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsKricker, Jennifer A
Page, Clive P
Gardarsson, Fridrik Runar
Parnham, Michael J
MetadataShow full item record
CitationKricker JA, Page CP, Gardarsson FR, Baldursson O, Gudjonsson T, Parnham MJ. Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacol Rev. 2021;73(4):233-262. doi:10.1124/pharmrev.121.000300
AbstractMacrolides are among the most widely prescribed broad spectrum antibacterials, particularly for respiratory infections. It is now recognized that these drugs, in particular azithromycin, also exert time-dependent immunomodulatory actions that contribute to their therapeutic benefit in both infectious and other chronic inflammatory diseases. Their increased chronic use in airway inflammation and, more recently, of azithromycin in COVID-19, however, has led to a rise in bacterial resistance. An additional crucial aspect of chronic airway inflammation, such as chronic obstructive pulmonary disease, as well as other inflammatory disorders, is the loss of epithelial barrier protection against pathogens and pollutants. In recent years, azithromycin has been shown with time to enhance the barrier properties of airway epithelial cells, an action that makes an important contribution to its therapeutic efficacy. In this article, we review the background and evidence for various immunomodulatory and time-dependent actions of macrolides on inflammatory processes and on the epithelium and highlight novel nonantibacterial macrolides that are being studied for immunomodulatory and barrier-strengthening properties to circumvent the risk of bacterial resistance that occurs with macrolide antibacterials. We also briefly review the clinical effects of macrolides in respiratory and other inflammatory diseases associated with epithelial injury and propose that the beneficial epithelial effects of nonantibacterial azithromycin derivatives in chronic inflammation, even given prophylactically, are likely to gain increasing attention in the future. SIGNIFICANCE STATEMENT: Based on its immunomodulatory properties and ability to enhance the protective role of the lung epithelium against pathogens, azithromycin has proven superior to other macrolides in treating chronic respiratory inflammation. A nonantibiotic azithromycin derivative is likely to offer prophylactic benefits against inflammation and epithelial damage of differing causes while preserving the use of macrolides as antibiotics.
RightsCopyright © 2021 by The Author(s).
- The immunomodulatory effects of macrolide antibiotics in respiratory disease.
- Authors: Pollock J, Chalmers JD
- Issue date: 2021 Dec
- Azithromycin: mechanisms of action and their relevance for clinical applications.
- Authors: Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R
- Issue date: 2014 Aug
- Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond.
- Authors: Poddighe D, Aljofan M
- Issue date: 2020 Jan-Dec
- Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.
- Authors: Khezri MR, Zolbanin NM, Ghasemnejad-Berenji M, Jafari R
- Issue date: 2021 Aug 15